G

ood morning, everyone, and welcome to the middle of the week. You should be congratulated on making it this far and remember: There are only a few more days until the weekend arrives. So keep at it. Besides, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation — we are still enjoying vanilla macadamia nut, for those who track this sort of thing. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a smashing day and please do stay in touch …

GSK is looking to sell certain operations, including its cephalosporins antibiotics business and some nutrition brands. A sale of the cephalosporin business would include at least three manufacturing plants, although the number of jobs that would be affected was not disclosed. The drug maker plans to sell its Horlicks and MaxiNutrition brands in the U.K., which will eliminate 320 jobs. At the same time, GSK will invest $180 million to expand manufacturing for respiratory and HIV drugs.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • In regards to “A sale of the [GSK] cephalosporin business would include at least three manufacturing plants.” This shedding has been going on for some time, I think. If memory serve me correctly, GSK had an anti-infectives facility for similar actives on the former SKB campus in PA. When I went to the wrong gate there out of habit to attend an ISPE event roughly 5+ years ago, “Building 42” had been leveled and turned into a parking lot sometime before.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.